Michael Wernecke, BA (he/him/his)

Senior Research Manager
Acumen, LLC
Los Angeles, United States

Disclosure information not submitted.

Presentation(s):

• Added Benefit and Waning Effectiveness of a Third-Dose mRNA COVID-19 Vaccine in Community-Dwelling Medicare Beneficiaries Aged ≥65 Years in Omicron Period

  Tuesday, August 27, 2024
  8:15 AM – 8:30 AM CEST

• Effectiveness Over Time of a Complete Primary Series of the Original, Monovalent COVID-19 Vaccines Among Adults Aged 18-64 Years in the United States

  Tuesday, August 27, 2024
  9:15 AM – 9:30 AM CEST